3RIK

The acid beta-glucosidase active site exhibits plasticity in binding 3,4,5,6-tetrahydroxyazepane-based inhibitors: implications for pharmacological chaperone design for gaucher disease

Changes made to a PDB entry after its initial release are considered to be either “major” or “minor”. The latest minor version of each major version is available as a file download. More information about the PDB versioning is available.

Version Number	Version Date	Version Type/Reason	Version Change	Revised CIF Category
1.0	2012-03-14	Initial release
1.1	2012-12-05		Derived calculations
1.2	2018-08-15		Advisory, Data collection, Derived calculations	pdbx_distant_solvent_atoms, pdbx_struct_assembly, pdbx_struct_assembly_gen, pdbx_struct_assembly_prop
1.3	2020-07-29	Remediation / Carbohydrate remediation	Data collection, Database references, Derived calculations, Structure summary	chem_comp, entity, pdbx_chem_comp_identifier, pdbx_entity_nonpoly, struct_conn, struct_ref_seq_dif, struct_site, struct_site_gen
1.4	2024-10-09		Data collection, Database references, Structure summary	chem_comp, chem_comp_atom, chem_comp_bond, database_2, pdbx_entry_details, pdbx_modification_feature	Download

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.